Opinion

Erman Akkus: My list of gastroesophageal cancer trials from the second half of 2024

Erman Akkus/X

Jan 2, 2025, 16:45

Erman Akkus: My list of gastroesophageal cancer trials from the second half of 2024

Erman Akkus, Medical oncology fellow at the Ankara University, shared a post on X:

“My list of gastroesophageal cancer trials from the second half of 2024
(Let’s give a start 2025)

1. JCOG1109 NExT
– Locally advanced esophageal SCC, neoadj. 3-year OS, DCF > CF, CF+RT = CF

2. RATIONALE-305
– Advanced gastric/GEJ adenoca, Tislelizumab plus ChT vs ChT, OS benefit

3. ATTRACTION-5
– Resected stage III gastric/GEJ, adjuvant nivolumab plus ChT vs ChT, no RFS benefit

4. ESCORT-NEO/NCCES01
– Esophageal SCC, neoadjuvant camrelizumab plus ChT vs ChT, higher pCR rates

5. RELATIVITY-060
– Advanced gastric/GEJ, 1L relatlimab + nivo +ChT vs nivo+ChT, no benefit

6. PLATFORM
– Advanced esophagogastric, maintenance durvalumab after 1L ChT, no benefit

7. INTEGRATE
Refractory advanced gastric cancer, regorafenib vs. placebo, statistically significant but little benefit

8. DRAGON IV/CAP 05
– Locally advanced gastric cancer, perioperative camrelizumab plus SOX vs SOX, pCR benefit

9. TOPGEAR
– Resectable gastric cancer, addition of preoperative CRT to ChT, No OS benefit

10. VESTIGE
– Gastric/GEJ, neoadj. FLOT, surgery then adjuvant nivolumab+ipilimumab vs ChT, No DFS benefit.”

Erman Akkus is a medical oncology fellow at the Ankara University, Faculty of Medicine. Previously, he was an Internal Medicine Resident at the Ankara University, Faculty of Medicine. He was also a Visiting Researcher at the University of Oslo. He completed his education from the Medical University of Vienna.